Expect closer supervision of US biologics settlements in wake of Humira ‘reverse payment’ concerns
Two US senators have called on the Federal Trade Commission (FTC) to examine patent settlements involving biologic and biosimilar producers, echoing calls from patient advocacy groups. Raising particular concerns about AbbVie’s recent high-profile…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.